Canadian Stocks Rise 0.6%
Dow Jones2026/10/21 20:31This article was automatically generated by Dow Jones using technology from Automated Insights.
Stocks in Canada rose Wednesday, as the S&P/TSX Composite Index increased 0.6% to 36324.99.
Among large local companies, AbraSilver Resource was the biggest leader during the session, jumping 12%, and BlackBerry surged 6.2%. Mullen Group rounded out the top three movers, as shares surged 5.7%.
Ivanhoe Mines was the biggest laggard, plunging 6.2%, followed by shares of Cascades Inc, which declined 4.3%. Shares of Magna International fell 4.1%.
U.S. stock indexes rose with the Nasdaq Composite Index increasing 1.1%. Meanwhile, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 Index added 0.6%.
On the currency front, the WSJ Dollar Index was flat at 96.91. The Canadian dollar strengthened 0.1% against the U.S. dollar to US$0.71.
In the bond markets, the 10-year Canadian government bond yield fell 2.54 basis points to 3.865%.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 21, 2026 16:31 ET (20:31 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
